KRAS-mutant cancers: Potential target could overcome treatment resistance

Researchers at The University of Texas MD Anderson Cancer Center have identified a specific protein, RASH3D19, that is responsible for activation of RAS signaling pathways involved in aggressive tumor growth and resistance to KRAS inhibitors in…

Continue Reading

News Source: medicalxpress.com